Table 1.
IC50 and percentage of inhibition of VEGF-induced VEGFR-2 activation by indolic compounds.
| Compounds | Concentrations (mM) | % Inhibition | IC50 (mM) | ||
|---|---|---|---|---|---|
| A | B | C | |||
| Melatonin | 0.001 | 13.12 ± 4.47 | ND | ND | ND |
| 0.01 | 12.85 ± 0.95 | ND | ND | ||
| 0.1 | 24.36 ± 1.57 | 0.68 ± 3.35 | NI | ||
| 1 | 32.15 ± 1.87 | 16.66 ± 1.9 | 13.86 ± 1.12 | ||
| 3-Indolacetic acid | 0.1 | 19.41 ± 4.19 | NI | 17.68 ± 2.99 | 0.9704 (0.7174–1.313) |
| 1 | 53.56 ± 1.39 | 10.34 ± 1.55 | 55.94 ± 3.64 | ||
| Serotonin | 0.1 | 20.21 ± 9.47 | NI | 6.16 ± 5.66 | ND |
| 1 | 29.56 ± 14.36 | NI | 23.33 ± 2.29 | ||
| 5-hydroxytryptophol | 0.1 | 34.37 ± 2.11 | 11.95 ± 2.50 | 32.51 ± 3.08 | ND |
| 1 | 22.99 ± 7.02 | NI | 32.58 ± 8.09 | ||
ND: non-determined. NI: non-inhibition. 95% confidence intervals for the IC50 values are shown in parentheses. HUVECs incubated with indolic compounds for (A,B) 4 h and (C) 24 h before stimulation with VEGF (25 ng/mL) for 5 min. (B) Additional washing step with PBS included just before stimulation with VEGF (25 ng/mL).